Skip to content
Perindopril
Aceon, Prestalia (perindopril) is a small molecule pharmaceutical. Perindopril was first approved as Aceon on 1993-12-30. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Combinations
Prestalia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amlodipine besylate
+
Perindopril arginine
Tradename
Company
Number
Date
Products
PRESTALIAAdhera TherapeuticsN-205003 RX2015-01-21
3 products, RLD, RS
Perindopril erbumine
Tradename
Company
Number
Date
Products
ACEONSymplmed PharmaceuticalsN-020184 DISCN1993-12-30
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aceonNew Drug Application2013-03-11
perindopril erbumineANDA2022-11-08
prestaliaNew Drug Application2019-10-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic nephropathiesEFO_0000401D003928—
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
left ventricular dysfunction—D018487—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Amlodipine Besylate / Perindopril Arginine, Prestalia, Adhera
78469612029-10-05DS, DPU-3
66964812023-04-15DS, DPU-3
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09A: Ace inhibitors, plain
— C09AA: Ace inhibitors, plain
— C09AA04: Perindopril
— C09B: Ace inhibitors, combinations
— C09BA: Ace inhibitors and diuretics
— C09BA04: Perindopril and diuretics
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB04: Perindopril and amlodipine
— C09BX: Ace inhibitors, other combinations in atc
— C09BX01: Perindopril, amlodipine and indapamide
— C09BX02: Perindopril and bisoprolol
— C09BX04: Perindopril, bisoprolol and amlodipine
— C10: Lipid modifying agents
— C10B: Lipid modifying agents, combinations
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX11: Atorvastatin, amlodipine and perindopril
— C10BX12: Atorvastatin, acetylsalicylic acid and perindopril
— C10BX13: Rosuvastatin, perindopril and indapamide
— C10BX14: Rosuvastatin, amlodipine and perindopril
— C10BX15: Atorvastatin and perindopril
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10—3111—15
Essential hypertensionD000075222I10——4138
Type 2 diabetes mellitusD003924EFO_0001360E11——13—4
Heart failureD006333EFO_0003144I5011—113
Chronic renal insufficiencyD051436N18———2—2
Blood pressureD001794EFO_0004325———2—2
DyslipidemiasD050171HP_0003119——11—2
Marfan syndromeD008382Orphanet_558Q87.4——11—2
Myocardial infarctionD009203EFO_0000612I21———1—1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81———1—1
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——1—12
Dilated cardiomyopathyD002311EFO_0000407I42.0——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5012———2
Sedentary behaviorD057185—1———1
AgingD000375GO_0007568R41.81—1———1
Alzheimer diseaseD000544EFO_0000249F03—1———1
Abdominal aortic aneurysmD017544EFO_0004214—1———1
ObesityD009765EFO_0001073E66.9—1———1
Colorectal neoplasmsD015179—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4———15
Therapeutic equivalencyD0138102————2
Substance-related disordersD019966EFO_0003890F131————1
Post-traumatic stress disordersD013313EFO_0001358F43.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Patient participationD010358————11
Coronary diseaseD003327————11
Subdural hematoma chronicD020200————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePERINDOPRIL
INNperindopril
Description
Perindopril is an alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is an alpha-amino acid ester, a dicarboxylic acid monoester, an organic heterobicyclic compound and an ethyl ester. It is a conjugate acid of a perindopril(1-).
Classification
Small molecule
Drug classantihypertensives (ACE inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
Identifiers
PDB—
CAS-ID82834-16-0
RxCUI54552
ChEMBL IDCHEMBL1581
ChEBI ID8024
PubChem CID107807
DrugBankDB00790
UNII IDY5GMK36KGY (ChemIDplus, GSRS)
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
1636
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Q7M4L4
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Prestalia - Adhera Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,909 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aceon, Perindopril erbumine, Prestalia
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,970 adverse events reported
View more details